

Daily evidence digest

21 March 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

SARS-CoV-2 transmission from mother-to-child, COVID-19 and cardiovascular disease, hospitalisation and death with Omicron and Delta

Peer reviewed journals featured:

- A systematic review on SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission [here](#) and associated editorial [here](#)
- Randomised trials of:
 - Favipiravir plus interferon-beta vs lopinavir/ritonavir plus interferon-beta [here](#)
 - Virtual reality to reduce COVID-19 vaccine hesitancy [here](#)
- A narrative review of COVID-19 and cardiovascular disease [here](#)
- Observational studies on:
 - The risks of hospitalisation and death associated with Omicron and Delta variants in England [here](#)
 - COVID-19 vaccine-induced immune responses and breakthrough infections in inflammatory bowel disease patients treated with infliximab and vedolizumab [here](#)
 - Association between COVID-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events [here](#) and associated editorial [here](#)
 - Durability of Johnson & Johnson (Janssen) vaccine in preventing COVID-19 infections and hospitalisations during the Delta surge in the US [here](#)
 - Cerebral venous thrombosis incidence after SARS-CoV-2 infection vs mRNA vaccination in Singapore [here](#)
 - Trends in hospitalisations for ambulatory care-sensitive conditions during COVID-19 in Michigan [here](#)
- Modelling studies exploring:
 - Reactive vaccination of workplaces and schools against COVID-19 [here](#)
 - Estimates of COVID-19's generation interval based on incidence rate, and optimal quarantine duration [here](#)

Letters and correspondence discussed:

- Myocarditis following a third Comirnaty (Pfizer) vaccine dose in military recruits in Israel [here](#)

Pre-peer review articles featured:

- Omicron BA.1 and BA.2 neutralising activity elicited in humans by seven vaccines [here](#)

Guidance and reports

- The World Health Organization published:
 - A guide on risk communication and community engagement for COVID-19 vaccination [here](#)
 - FAQs on the Global Influenza Surveillance and Response System (GISRS) sentinel surveillance for COVID-19 [here](#)
- The National COVID-19 Clinical Evidence Taskforce released recommendations on:
 - Disease-modifying treatments for pregnant or breastfeeding women with COVID-19 [here](#)
 - Risk classification tool for adults with mild COVID-19 [here](#)
 - Ivermectin FAQs [here](#)

News and blogs

- Scientists struggle to probe COVID-19's origins amid sparse data from China [here](#)
- Are chilblains or 'COVID toes' actually caused by the coronavirus? [here](#)
- Evusheld (AstraZeneca) is approved in UK for prophylaxis in immunocompromised people [here](#)
- Pfizer asks the US regulator to authorise fourth vaccine dose for over 65s [here](#)
- Hong Kong reports world's highest death rate as zero-covid strategy fails [here](#)
- The TGA is undertaking a post-market review of COVID-19 tests to detect emerging SARS-CoV-2 variants [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).